Acute Porphyria Drugs

C09AA08 - Cilazapril

Probably not porphyrinogenic
PNP

Rationale
No evidence of significant CYP-dependent metabolism. Occasional observations of tolerance. Two references stating (probable) non-porphyrinogenicity. Risk for gastrointestinal adverse event in the form of nausea motivates vigilance against insufficient intake of food, especially of carbohydrate.
Chemical description
Hydrolyzed to cilazaprilate, a long term ACE-inhibitor. Excreted (90%) in unchanged form by the kidneys.
Therapeutic characteristics
A common side effect that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack is nausea. Other common side effects are headache and fatigue.
Personal communication
Andersson, patient report (n=2): tolerated.
Similar drugs
Explore alternative drugs in similar therapeutic classes C09A / C09AA or go back.
References
# Citation details PubMed ID
Porphyria Drug Lists
1. French List
Centre Français des Porphyries
2. South African List
Porphyria South Africa No longer maintained
Tradenames

Inhibace Inocar Inhibace Inibace · Initiss Inhibace Cilazapril · Vascace Inhibace Cazaprol · Cilan · Inhibace · Symibace Cilazapril · Inhibace · Zapril Cilazapril · Inhibace Prilazid Cilazil Cazaprol · Inhibace Inhibace · Vascace Cilazapril
In cooperation with Ipnet
© Napos 2026
An unhandled error has occurred. Reload 🗙